Kodiak Sciences Reports Positive DAYBREAK Results for Zenkuda and KSI-501 in Wet AMD
Kodiak Sciences reported that Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) met the primary goal of the late-stage DAYBREAK study in patients with wet age-related macular degeneration. The study evaluated the investigational treatments against aflibercept (Eylea), and the report characterized Zenkuda as providing immediate relief after administration with durable therapeutic benefits.
The development is retained as a valid, forward-looking clinical milestone because tradingview_news/175978 explicitly reports Kodiak Sciences’ announcement that Zenkuda and KSI-501 met the primary goal of a late-stage wet-AMD study and describes Zenkuda’s immediate and durable effects; such a result can change regulatory and commercialization probabilities. Stock-performance language is excluded, and the planned BLA filing is not bundled into this atomic trial-result development. Confidence is high but below maximum because a separate supplied grounding note says the positive claims were not independently verified; the timestamp is therefore treated as the best available estimate based on the 11:31 UTC report time. The prior event match is retained because this is the results milestone following the scheduled DAYBREAK readout. KOD is directly affected, while REGN is approved because the study used Regeneron’s Eylea/aflibercept comparator; broader competitors and manufacturing names are too indirect or speculative.
Kodiak Sciences nannounced that Zenkuda and KSI-501, two experimental treatments for wet age-related macular degeneration, met their primary goal in a late-stage study. Zenkuda, in particular, demonstrated "a potential new standard-of-care profile," delivering relief immediately after administration along with long-lasting therapeutic benefits.
Shares of Kodiak Sciences surged more than 170% Monday-on pace for its largest one-day increase on record-after the company announced its eye drug matched Regeneron's blockbuster Eylea in a Phase 3 trial.
Palo Alto, Calif.-based Kodiak said that more than half of patients with wet age-related macular degeneration who took its experimental drug Zenkuda went six months between eye injections. whereas Eylea patients typically get a shot every two months.
Kodiak said it plans to seek FDA approval for Zenkuda in the fourth quarter.